Shots:

• The collaboration leads to the starting of pre-clinical testing of multiple vaccine prospects- intending to identify the vaccine candidate for clinical studies- by the month-end
• Janssen will utilize its AdVac and PER.C6 technologies (technologies that were used to develop Ebola- Zika- RSV- & HIV vaccine) for rapidly upscale production of an optimal vaccine candidate. J&J is expected to initiate the P-I clinical study by the end of the year
• J&J is in collaboration with global strategic partners to screen its antiviral molecules’ library for accelerating the discovery of COVID-19 treatments

Click here ­to­ read full press release/ article | Ref: J&J | Image: The Pharma Times